Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into ph
Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT),
UK biotech Celleron Therapeutics has bought a licence to develop, manufacture and market emactuzumab, an unwanted drug from Roche’s pipeline that could be used in a rare tendon sheath cance
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.